0 Table of Contents |
1 Home |
2 Patient Information |
3 Disease Characterization |
4 Assessment |
5 Genomics |
6 Treatments |
7 Outcomes |
8 Conformance Expectations |
9 Identifying In-Scope Patients |
10 Profile Conformance |
11 Terminology |
12 Data Dictionary |
13 Profiles |
14 Extensions |
15 Value Sets |
16 Code Systems |
17 Capability Statements |
18 Artifacts Summary |
18.1 mCODE Data Receiver CapabilityStatement: Get in-scope patients (and associated Conditions) using _include |
18.2 mCODE Data Receiver CapabilityStatement: Get in-scope patients using reverse chaining |
18.3 mCODE Data Receiver: Get Bundle for a Patient |
18.4 mCODE Data Receiver: Get Conditions then Patients |
18.5 mCODE Data Receiver: Get Patients in Group |
18.6 mCODE Data Sender CapabilityStatement: Get in-scope patients (and associated Conditions) using _include |
18.7 mCODE Data Sender CapabilityStatement: Get in-scope patients using reverse chaining |
18.8 mCODE Data Sender: Get Bundle for a Patient |
18.9 mCODE Data Sender: Get Conditions then Patients |
18.10 mCODE Data Sender: Get Patients in Group |
18.11 Fetch mCODE Patient Bundle for a given Patient |
18.12 Search by code:in in Conditions |
18.13 Cancer Stage Profile |
18.14 Parent for T, N, and M Categories. |
18.15 Cancer Disease Status Profile |
18.16 Cancer Patient Profile |
18.17 Cancer-Related Medication Administration Profile |
18.18 Cancer-Related Medication Request Profile |
18.19 Cancer-Related Surgical Procedure Profile |
18.20 CLL Binet Stage Profile |
18.21 CLL Rai Stage Profile |
18.22 Comorbidities Profile |
18.23 ECOG Performance Status Profile |
18.24 Genomic Region Studied Profile |
18.25 Genomic Variant Profile |
18.26 Genomics Report Profile |
18.27 Gynecologic Tumor FIGO Stage Profile |
18.28 History of Metastatic Cancer |
18.29 Human Specimen Profile |
18.30 Karnofsky Performance Status Profile |
18.31 Lymphoma Stage Profile |
18.32 mCODE Patient Bundle Profile |
18.33 mCODE Patient Group Profile |
18.34 Melanoma Breslow Depth Stage Profile |
18.35 Melanoma Clark Level Profile |
18.36 Myeloma ISS Stage Profile |
18.37 Myeloma RISS Stage Profile |
18.38 Primary Cancer Condition Profile |
18.39 Prostate Gleason Grade Group Profile |
18.40 Radiotherapy Course Summary Profile |
18.41 Radiotherapy Volume Profile |
18.42 Secondary Cancer Condition Profile |
18.43 TNM Distant Metastases Category Profile |
18.44 TNM Primary Tumor Category Profile |
18.45 TNM Regional Nodes Category Profile |
18.46 TNM Stage Group Profile |
18.47 Tumor Marker Test Profile |
18.48 Tumor Profile |
18.49 Tumor Size Profile |
18.50 Body Structure Identifier Profile |
18.51 Body Location Qualifier Extension |
18.52 Cancer Disease Status Evidence Type Extension |
18.53 Histology-Morphology-Behavior Extension |
18.54 Laterality Qualifier Extension |
18.55 Procedure Intent Extension |
18.56 Radiotherapy Dose Delivered To Volume Extension |
18.57 Radiotherapy Modality And Technique Extension |
18.58 Radiotherapy Modality Extension |
18.59 Radiotherapy Number of Sessions Extension |
18.60 Radiotherapy Technique Extension |
18.61 Related Condition Absent Extension |
18.62 Related Condition Extension |
18.63 Treatment Termination Reason Extension (deprecated) |
18.64 Benign Neoplasm of Brain and CNS Disorder Value Set |
18.65 Binet Stage Value Set |
18.66 Body Location and Laterality Qualifier Value Set |
18.67 Body Location Qualifier Value Set |
18.68 Brachytherapy High Dose Rate Electronic Technique Value Set |
18.69 Brachytherapy High Dose Rate Technique Value Set |
18.70 Brachytherapy Low Dose Rate Temporary Radation Technique Value Set |
18.71 Brachytherapy Modality Value Set |
18.72 Brachytherapy Permanent Seeds Technique Value Set |
18.73 Brachytherapy Pulsed Dose Rate Technique Value Set |
18.74 Brachytherapy Radiopharmaceutical Technique Value Set |
18.75 Brachytherapy Technique Value Set |
18.76 Breslow Depth Stage Value Set |
18.77 Cancer Body Location Value Set |
18.78 Cancer Disease Status Evidence Type Value Set |
18.79 Cancer Disorder Value Set |
18.80 Cancer Stage Type Value Set |
18.81 Cancer Stage Value Set |
18.82 Cancer Staging Method Value Set |
18.83 Cancer-Related Surgical Procedure Value Set |
18.84 Carbon Ion Beam Technique Value Set |
18.85 Carcinoma In-Situ Disorder Value Set |
18.86 Clark Level Value Set |
18.87 Clinical or Pathologic Modifier |
18.88 Condition Status Trend Maximum Value Set |
18.89 Condition Status Trend Value Set |
18.90 Cytologic Evidence of Malignancy Value Set |
18.91 Electron Beam Technique Value Set |
18.92 FAB Classification Value |
18.93 FIGO Stage Value Set |
18.94 FIGO Staging Method Value Set |
18.95 Gleason Grade Value Set |
18.96 Histology Morphology Behavior Value Set |
18.97 History of Metastatic Malignant Neoplasm Value Set |
18.98 Human Specimen Type Value Set |
18.99 International Staging System (ISS) for Myeloma Stage Value Set |
18.100 Laterality Qualifier Value Set |
18.101 Lymphoma Stage Value Modifier Value Set |
18.102 Lymphoma Stage Value Set |
18.103 Lymphoma Staging System Value Set |
18.104 Melanoma In-Situ Disorder Value Set |
18.105 Neutron Beam Technique Value Set |
18.106 Photon Beam Technique Value Set |
18.107 Primary Cancer Disorder Value Set |
18.108 Primary Malignant Neoplasm Disorder Value Set |
18.109 Procedure Intent Value Set |
18.110 Proton Beam Technique Value Set |
18.111 Radiotherapy Modality Value Set |
18.112 Radiotherapy Technique Value Set |
18.113 Radiotherapy Treatment Location Qualifier Value Set |
18.114 Radiotherapy Treatment Location Value Set |
18.115 Radiotherapy Volume Type Value Set |
18.116 Rai Stage Value Set |
18.117 Rai Staging System Value Set |
18.118 Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set |
18.119 Secondary Cancer Disorder Value Set |
18.120 Specific Diagnosis of Cancer Value Set |
18.121 Teleradiotherapy Modality Value Set |
18.122 Teleradiotherapy Technique Value Set |
18.123 TNM Distant Metastases Category Value Set |
18.124 TNM Distant Metastases Maximum Value Set |
18.125 TNM Distant Metastases Staging Type Maximum Value Set |
18.126 TNM Distant Metastases Staging Type Value Set |
18.127 TNM Primary Tumor Category Value Set |
18.128 TNM Primary Tumor Maximum Value Set |
18.129 TNM Primary Tumor Staging Type Maximum Value Set |
18.130 TNM Primary Tumor Staging Type Value Set |
18.131 TNM Regional Nodes Category Value Set |
18.132 TNM Regional Nodes Maximum Value Set |
18.133 TNM Regional Nodes Staging Type Maximum Value Set |
18.134 TNM Regional Nodes Staging Type Value Set |
18.135 TNM Stage Group Maximum Value Set |
18.136 TNM Stage Group Staging Type Maximum Value Set |
18.137 TNM Stage Group Staging Type Value Set |
18.138 TNM Stage Group Value Set |
18.139 TNM Staging Method Value Set |
18.140 Treatment Termination Reason Value Set |
18.141 Tumor Marker Test Value Set |
18.142 Tumor Morphology Code Max Value Set |
18.143 Tumor Morphology Code Value Set |
18.144 Tumor Size Method Value Set |
18.145 Tumor Size Units Value Set |
18.146 Requested SNOMED Codes Code System |
18.147 TG263 Concept Map |
18.148 binet-stage-group-A |
18.149 bodyheight-jenny-m-2018-03-06 |
18.150 bodyweight-jenny-m-2018-03-16 |
18.151 bodyweight-jenny-m-2018-04-22 |
18.152 cancer-disease-status-improved |
18.153 cancer-disease-status-jenny-m |
18.154 cancer-patient-adam-everyman |
18.155 cancer-patient-eve-anyperson |
18.156 cancer-patient-jenny-m |
18.157 cancer-patient-john-anyperson |
18.158 cancer-related-comorbidities-jenny-m |
18.159 cancer-related-comorbidities-john-anyperson |
18.160 cancer-related-medication-admin-cyclophosphamide-jenny-m |
18.161 cancer-related-medication-admin-doxorubicin-jenny-m |
18.162 cancer-related-medication-admin-paclitaxel-jenny-m |
18.163 cancer-related-medication-request-anastrozole-jenny-m |
18.164 cancer-related-medication-request-cisplatin |
18.165 cancer-related-medication-request-cisplatin-stopped |
18.166 cancer-related-medication-request-cyclophosphamide-jenny-m |
18.167 cancer-related-medication-request-doxorubicin-jenny-m |
18.168 cancer-related-medication-request-gefitinib |
18.169 cancer-related-medication-request-paclitaxel-jenny-m |
18.170 cancer-related-surgical-procedure-jenny-m |
18.171 cancer-related-surgical-procedure-lobectomy |
18.172 ecog-performance-status-fully-active |
18.173 ecog-performance-status-jenny-m |
18.174 family-member-history-aunt-jenny-m |
18.175 family-member-history-sister-jenny-m |
18.176 family-member-history-uncle-jenny-m |
18.177 figo-stage-IIIA |
18.178 genomic-region-studied-jenny-m |
18.179 genomic-region-studied-stk11 |
18.180 genomic-variant-fusion |
18.181 genomic-variant-germline-deletion |
18.182 genomic-variant-jenny-m |
18.183 genomic-variant-somatic-single-nucleotide |
18.184 genomics-report-jenny-m |
18.185 genomics-report-john-anyperson |
18.186 gleason-grade-group-4 |
18.187 gx-cancer-patient-adam-anyperson |
18.188 gx-genomic-bundle-adam-anyperson |
18.189 gx-genomic-diagnostic-implication-bap1 |
18.190 gx-genomic-diagnostic-implication-pof1b |
18.191 gx-genomic-diagnostic-implication-polrmt |
18.192 gx-genomic-msi |
18.193 gx-genomic-specimen-tumornormal-normal |
18.194 gx-genomic-specimen-tumornormal-tumor |
18.195 gx-genomic-therapeutic-implication-alectinib |
18.196 gx-genomic-therapeutic-implication-brigatinib |
18.197 gx-genomic-therapeutic-implication-ceritinib |
18.198 gx-genomic-therapeutic-implication-crizotinib |
18.199 gx-genomic-therapeutic-implication-lorlatinib |
18.200 gx-genomic-tmb |
18.201 gx-genomic-variant-fusion-met-alk |
18.202 gx-genomic-variant-pertinent-negative-nras-kit-braf |
18.203 gx-genomic-variant-somatic-bap1-indel |
18.204 gx-genomic-variant-somatic-cdkn2a-cnv |
18.205 gx-genomic-variant-somatic-cdkn2b-cnv |
18.206 gx-genomic-variant-somatic-kdm5d |
18.207 gx-genomic-variant-somatic-mtap |
18.208 gx-genomic-variant-somatic-mycn |
18.209 gx-genomic-variant-somatic-pof1b |
18.210 gx-genomic-variant-somatic-polrmt |
18.211 gx-genomics-report-adam-anyperson |
18.212 gx-order-tumornormal-gensop-inc |
18.213 gx-practitioner-test-pathologist |
18.214 gx-us-core-organization-gensop-inc |
18.215 history-of-cancer-metastatic-to-liver |
18.216 hodgkins-lymphoma-stage-IIIe |
18.217 human-specimen-left-breast-jenny-m |
18.218 human-specimen-lung |
18.219 jenny-m-chest-wall-lymph-nodes-treatment-volume |
18.220 jenny-m-chest-wall-treatment-volume |
18.221 john-anyperson-chf |
18.222 john-anyperson-treatment-volume |
18.223 karnofsky-performance-status-normal-activity |
18.224 lab-result-observation-hemoglobin |
18.225 mCODE Patient Group Example |
18.226 mcode-patient-bundle-jenny-m |
18.227 melanoma-breslow-depth-stage |
18.228 melanoma-clark-level-4 |
18.229 multiple-myeloma-iss-stage-II |
18.230 multiple-myeloma-riss-stage-II |
18.231 no-history-of-metastatic-cancer |
18.232 observation-smoking-pack-years-jenny-m |
18.233 primary-cancer-condition-breast |
18.234 primary-cancer-condition-cll |
18.235 primary-cancer-condition-jenny-m |
18.236 primary-cancer-condition-nonspecific |
18.237 primary-cancer-condition-nsclc |
18.238 radiotherapy-treatment-summary-chest-wall-jenny-m |
18.239 radiotherapy-treatment-summary-other-with-text |
18.240 rai-stage-II |
18.241 secondary-cancer-condition-brain-mets |
18.242 tnm-clinical-distant-metastases-category-cM0 |
18.243 tnm-clinical-distant-metastases-category-jenny-m |
18.244 tnm-clinical-primary-tumor-category-cT3 |
18.245 tnm-clinical-primary-tumor-category-jenny-m |
18.246 tnm-clinical-regional-nodes-category-cN3 |
18.247 tnm-clinical-regional-nodes-category-jenny-m |
18.248 tnm-clinical-stage-group-3c |
18.249 tnm-clinical-stage-group-jenny-m |
18.250 tnm-pathologic-distant-metastases-category-jenny-m |
18.251 tnm-pathologic-primary-tumor-category-jenny-m |
18.252 tnm-pathologic-regional-nodes-category-jenny-m |
18.253 tnm-pathologic-stage-group-jenny-m |
18.254 tumor-lobular-carcinoma-left-breast |
18.255 tumor-marker-test-egf |
18.256 tumor-marker-test-er-jenny-m |
18.257 tumor-marker-test-her2-jenny-m |
18.258 tumor-marker-test-oncotype-dx-jenny-m |
18.259 tumor-marker-test-pr-jenny-m |
18.260 tumor-size-jenny-m |
18.261 tumor-size-pathology |
18.262 tumor-specimen-left-breast-jenny-m |
18.263 tumor-specimen-lobular-carcinoma-left-breast |
18.264 us-core-condition-anxiety-jenny-m |
18.265 us-core-condition-depression-jenny-m |
18.266 us-core-condition-hypertension-jenny-m |
18.267 us-core-diagnosticreport-lab-jenny-m |
18.268 us-core-observation-lab-neutrophils-jenny-m |
18.269 us-core-observation-lab-sentinel-nodes-jenny-m |
18.270 us-core-observation-lab-tumor-dcis-jenny-m |
18.271 us-core-observation-lab-tumor-grade-jenny-m |
18.272 us-core-observation-lab-tumor-invasion-jenny-m |
18.273 us-core-observation-lab-tumor-margins-jenny-m |
18.274 us-core-organization-bedrock-medicine |
18.275 us-core-organization-physician-services-inc |
18.276 us-core-practitioner-jane-radiotech |
18.277 us-core-practitioner-kyle-anydoc |
18.278 us-core-practitioner-mary-obgyn |
18.279 us-core-practitioner-nancy-oncology-nurse |
18.280 us-core-practitioner-owen-oncologist |
18.281 us-core-practitioner-peter-pathologist |
18.282 us-core-procedure-biopsy-jenny-m |
18.283 us-core-procedure-mammogram-jenny-m |
18.284 us-core-smokingstatus-jenny-m |
19 Basic Examples |
20 Genomics Examples |
21 Extended Example |
22 Release Notes |
23 Glossary |
24 Download Specification |